This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Antibody Technologies And Attrition Rates -- An Industry Analysis 2013

NEW YORK, March 27, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Antibody Technologies and Attrition Rates – an industry analysis 2013

http://www.reportlinker.com/p01154426/Antibody-Technologies-and-Attrition-Rates-–-an-industry-analysis-2013.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biopharmaceutical

Product Description

The report "Antibody Technologies and Attrition Rates – an industry analysis 2013" is based on the identification of the antibody generation technologies of 504 naked antibodies in clinical or market stages. Information was retrieved from scientific and corporate publications as well as from patent and legal literature. The report provides descriptive statistics of the 504 naked antibodies and their status during the study period of January 1, 2013 to February 28, 2013. The antibodies are categorized as active during the study period or discontinued during or before the study period. Attrition rates were calculated across a number of variables.

Descriptive statistics of the 504 naked antibodies include the following variables:

  • Unique antibody identifiers (drug codes; generic name; brand name)
  • Antibody format (full length, Fab, scFv, VH/VL, nanobody, bispecific, cocktail/polyclonal)
  • In vitro antibody generation technologies (display technologies from CAT, Dyax, Morphosys, BioInvent, Domantis, Genentech, others)
  • In vivo antibody generation technologies (chimeric, primatized, nanobodies, deimmunized, human engineered, humaneered, humanized, XenoMouse,
  • HuMab mouse, KM mouse, VelocImmune mouse, human B-cell derived)
  • Animal species of parental wild-type antibody (mouse, rat, rabbit, hamster, cynomolgus monkey, camelid)
  • Antibody status (active/discontinued)
  • Year of failure
  • Reason for failure (efficacy, pharmacokinetics/ADME; safety; technical, business, next generation, inactivity)
  • Target
  • Immunoglobulin class and IgG isotype
  • Highest phase
  • Therapeutic area of lead indication
  • Companies (developer, licensor/originator)

An Antibody Data Sheet was prepared for each unique antibody containing the retrieved information and the source of information in the form of a scientific reference or a hyperlink leading to the website from which the information was obtained.

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,416.85 +225.48 1.31%
S&P 500 2,021.25 +19.09 0.95%
NASDAQ 4,683.4070 +45.4130 0.98%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs